Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1886 1
1894 1
1908 1
1919 1
1942 1
1943 1
1945 1
1946 2
1947 7
1948 2
1949 2
1950 2
1951 9
1952 3
1953 8
1954 5
1955 9
1956 14
1957 5
1958 10
1959 9
1960 14
1961 11
1962 10
1963 15
1964 13
1965 13
1966 22
1967 14
1968 14
1969 20
1970 13
1971 17
1972 11
1973 13
1974 24
1975 13
1976 10
1977 19
1978 17
1979 16
1980 13
1981 10
1982 12
1983 6
1984 6
1985 2
1986 12
1987 7
1988 6
1989 8
1990 8
1991 11
1992 15
1993 11
1994 9
1995 16
1996 21
1997 14
1998 11
1999 15
2000 20
2001 17
2002 29
2003 23
2004 32
2005 27
2006 41
2007 25
2008 31
2009 33
2010 33
2011 38
2012 46
2013 45
2014 38
2015 56
2016 50
2017 56
2018 55
2019 62
2020 69
2021 67
2022 63
2023 76
2024 68

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,603 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP. Seymour JF, et al. Among authors: owen c. N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976. N Engl J Med. 2018. PMID: 29562156 Free article. Clinical Trial.
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. Among authors: owen c. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil SK, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists’ Clinical Standards Unit. Smith CH, et al. Among authors: owen cm. Br J Dermatol. 2020 Oct;183(4):628-637. doi: 10.1111/bjd.19039. Epub 2020 Jul 21. Br J Dermatol. 2020. PMID: 32189327 No abstract available.
Complex scaffold remodeling in plant triterpene biosynthesis.
De La Peña R, Hodgson H, Liu JC, Stephenson MJ, Martin AC, Owen C, Harkess A, Leebens-Mack J, Jimenez LE, Osbourn A, Sattely ES. De La Peña R, et al. Among authors: owen c. Science. 2023 Jan 27;379(6630):361-368. doi: 10.1126/science.adf1017. Epub 2023 Jan 26. Science. 2023. PMID: 36701471 Free PMC article.
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP. Niemann CU, et al. Among authors: owen c. Lancet Oncol. 2023 Dec;24(12):1423-1433. doi: 10.1016/S1470-2045(23)00452-7. Epub 2023 Nov 6. Lancet Oncol. 2023. PMID: 37944541 Clinical Trial.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Seymour JF, et al. Among authors: owen cj. Blood. 2022 Aug 25;140(8):839-850. doi: 10.1182/blood.2021015014. Blood. 2022. PMID: 35605176 Free PMC article. Clinical Trial.
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, Benjamini O, Janssens A, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Ysebaert L, Qin R, Steele AJ, Schuier N, Baeten K, Caces DB, Niemann CU. Kater AP, et al. Among authors: owen c. NEJM Evid. 2022 Jul;1(7):EVIDoa2200006. doi: 10.1056/EVIDoa2200006. Epub 2022 May 13. NEJM Evid. 2022. PMID: 38319255 Clinical Trial.
1,603 results